News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NanoBio Corporation to Collaborate in Research Effort for Respiratory Syncytial Virus Vaccine With Merck & Co., Inc. (MRK)


12/8/2011 9:34:40 AM

ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio Corporation today announced a preclinical collaboration with a subsidiary of Merck & Co., Inc., focused on the development of a vaccine for Respiratory Syncytial Virus (RSV). The studies will evaluate the combination of Merck’s proprietary RSV antigen with NanoBio’s NanoStat® adjuvant technology for use as an intranasal vaccine. As part of the agreement, Merck has the option to negotiate a non-exclusive license to the NanoStat® adjuvant for development of a commercial RSV vaccine.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES